{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:27:37Z","timestamp":1793291257309,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>In peptide receptor radionuclide therapy (PRRT) using lutetium-177-labeled DOTA-Tyr3-octreotate ([<jats:sup>177<\/jats:sup>Lu] DOTATATE), isolation is required until the external dose rate at 1\u00a0m (EDR-1\u00a0m) from the body surface falls below the regulatory standards of each country. While it is known that renal function influences EDR-1\u00a0m reduction within 180\u00a0min post-administration, the factors affecting EDR-1\u00a0m on the day following administration (Late EDR-1\u00a0m) remain unclear. This study aimed to identify factors influencing Late EDR-1\u00a0m after PRRT using [<jats:sup>177<\/jats:sup>Lu] DOTATATE for neuroendocrine tumors and to predict Late EDR-1\u00a0m using pretreatment [<jats:sup>111<\/jats:sup>In] pentetreotide single-photon emission computed tomography\/computed tomography (SPECT\/CT) data.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This study analyzed 111 PRRT cycles administered to 36 patients between September 2021 and August 2024. Late EDR-1\u00a0m was set as the dependent variable, whereas total radiopharmaceutical uptake (LUTtotal), dose per body weight, creatinine clearance (CCr), and albumin\u2013bilirubin (ALBI) score were set as the independent variables in the multiple regression analysis. LUTtotal was calculated using SPECT\/CT data acquired after the patient left the radiation therapy room, defining the volume of interest (VOI) as the area with SUVmean\u2009+\u20092SD or higher in the skeletal muscle. The VOI volume multiplied by the SUVmean was used to define LUTtotal. In addition, using [<jats:sup>111<\/jats:sup>In] pentetreotide SPECT\/CT data, the total radiopharmaceutical uptake (OCTtotal) was calculated in a manner similar to LUTtotal, and its correlation with LUTtotal was examined. A predictive equation for Late EDR-1\u00a0m was developed using the results of the multivariate analysis, and its performance was tested using subsequent cases between August 2024 and January 2025.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The median measured Late EDR-1\u00a0m was 8.0 (range, 4.0\u201326.0) \u03bcSv\/h. LUTtotal and dose per body weight were significantly correlated with Late EDR-1\u00a0m, whereas CCr and ALBI scores were not. Based on the results of the multivariate analysis, the predictive equation using the dose per body weight, assuming a dosage of 7400\u00a0MBq and OCTtotal, achieved a root mean square error (RMSE) of 2.24\u00a0\u03bcSv\/h. In subsequent test cases, the RMSE was 3.47\u00a0\u03bcSv\/h.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Late EDR-1\u00a0m is significantly correlated with LUTtotal and dose per body weight. It can be accurately predicted using [<jats:sup>111<\/jats:sup>In] pentetreotide SPECT\/CT data.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s12149-025-02044-5","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T01:41:44Z","timestamp":1743903704000},"page":"696-706","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Factors and predictors affecting late external dose rates and isolation period in patients after lutetium-177-labeled DOTA-Tyr3-octreotate treatment for neuroendocrine tumors"],"prefix":"10.1007","volume":"39","author":[{"given":"Naoto","family":"Wakabayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7930-0975","authenticated-orcid":false,"given":"Shiro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Tsuchikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamato","family":"Munakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junki","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohsuke","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,5]]},"reference":[{"key":"2044_CR1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s12149-018-1230-7","volume":"32","author":"M Hosono","year":"2018","unstructured":"Hosono M, Ikebuchi H, Nakamura Y, Nakamura N, Yamada T, Yanagida S, et al. Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.). Ann Nucl Med. 2018;32:217\u201335.","journal-title":"Ann Nucl Med"},{"key":"2044_CR2","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s12149-014-0843-8","volume":"28","author":"PJ Calais","year":"2014","unstructured":"Calais PJ, Turner JH. Radiation safety of outpatient 177Lu-octreotate radiopeptide therapy of neuroendocrine tumors. Ann Nucl Med. 2014;28:531\u20139.","journal-title":"Ann Nucl Med"},{"key":"2044_CR3","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1007\/s00259-011-1833-x","volume":"38","author":"J Kunikowska","year":"2011","unstructured":"Kunikowska J, Kr\u00f3licki L, Hubalewska-Dydejczyk A, Miko\u0142ajczak R, Sowa-Staszczak A, Pawlak D. Clinical results of radionuclide therapy of neuroendocrine tumours with 90 Y-DOTATATE and tandem 90 Y\/ 177 Lu-DOTATATE: Which is a better therapy option? Eur J Nucl Med Mol Imaging. 2011;38:1788\u201397.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2044_CR4","first-page":"813","volume":"49","author":"S Takano","year":"2022","unstructured":"Takano S, Kobayashi N, Ichikawa Y. Hata M [Indications and Practice of a New Radionuclide Therapy, 177Lu-DOTATATE in Japan]. Gan To Kagaku Ryoho. 2022;49:813\u201320.","journal-title":"Gan To Kagaku Ryoho"},{"key":"2044_CR5","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, et al. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024;403:2807\u201317.","journal-title":"Lancet"},{"key":"2044_CR6","doi-asserted-by":"publisher","first-page":"S954","DOI":"10.1016\/j.annonc.2022.07.1013","volume":"33","author":"E Baudin","year":"2022","unstructured":"Baudin E, Walter TA, Beron A, Smith D, Hadoux J, Lachachi C, et al. 887O First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionucleide therapy with 177Lutetium-Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: Results of the OCLURANDOM trial. Ann Oncol. 2022;33:S954.","journal-title":"Ann Oncol"},{"key":"2044_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1089\/thy.2017.0570","volume":"29","author":"P Li","year":"2019","unstructured":"Li P, Zhang A, Liu Y, Xu C, Tang L, Yuan H, et al. Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer: Study of External Dose Rate Attenuation Law and Individualized Patient Management. Thyroid. 2019;29:93\u2013100.","journal-title":"Thyroid"},{"key":"2044_CR8","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.7150\/ijms.58680","volume":"18","author":"J Zhang-Yin","year":"2021","unstructured":"Zhang-Yin J, Guilabert N, Kiffel T, Montravers F, Calais P, Lumbroso J, et al. Patient external dose rate after 177Lu-DOTATATE therapy: Factors affecting its decrease and predictive value. Int J Med Sci. 2021;18:2725\u201335.","journal-title":"Int J Med Sci"},{"key":"2044_CR9","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s002590100574","volume":"28","author":"DJ Kwekkeboom","year":"2001","unstructured":"Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, et al. [177Lu-DOTA0, Tyr3]octreotate: Comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med. 2001;28:1319\u201325.","journal-title":"Eur J Nucl Med"},{"key":"2044_CR10","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s12149-024-01962-0","volume":"38","author":"G Takai","year":"2024","unstructured":"Takai G, Hanaoka K, Nagano K, Okada T, Honda M, Komoto I. Prediction of 1\u00a0cm dose-equivalent rate on the day after administration of 177Lu-DOTATATE from 111In-somatostatine receptor scintigraphy prior to treatment. Ann Nucl Med. 2024;38:927\u201332.","journal-title":"Ann Nucl Med"},{"key":"2044_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31\u201341.","journal-title":"Nephron"},{"key":"2044_CR12","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","volume":"33","author":"PJ Johnson","year":"2015","unstructured":"Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. A nssessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach - The albi grade. J Clin Oncol. 2015;33:550\u20138.","journal-title":"J Clin Oncol"},{"key":"2044_CR13","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s00259-013-2504-x","volume":"40","author":"R Kashyap","year":"2013","unstructured":"Kashyap R, Jackson P, Hofman MS, Eu P, Beauregard JM, Zannino D, et al. Rapid blood clearance and lack of long-term renal toxicity of 177Lu-DOTATATE enables shortening of renoprotective amino acid infusion. Eur J Nucl Med Mol Imaging. 2013;40:1853\u201360.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2044_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0105682","volume":"9","author":"K Hirata","year":"2014","unstructured":"Hirata K, Kobayashi K, Wong KP, Manabe O, Surmak A, Tamaki N, et al. A semi-automated technique determining the liver standardized uptake value reference for tumor delineation in FDG PET-CT. PLoS ONE. 2014;9: e105682.","journal-title":"PLoS ONE"},{"key":"2044_CR15","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S1095-0397(99)00016-3","volume":"2","author":"SM Larson","year":"1999","unstructured":"Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, et al. Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging: The Visual Response Score and the Change in Total Lesion Glycolysis. Clin Positron Imaging. 1999;2:159\u201371.","journal-title":"Clin Positron Imaging"},{"key":"2044_CR16","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1007\/s12149-021-01674-9","volume":"35","author":"N Kobayashi","year":"2021","unstructured":"Kobayashi N, Takano S, Ito K, Sugiura M, Ogawa M, Takeda Y, et al. Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA0-Tyr3-octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumors. Ann Nucl Med. 2021;35:1332\u201341.","journal-title":"Ann Nucl Med"},{"key":"2044_CR17","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1093\/rpd\/ncac187","volume":"198","author":"M Bellamy","year":"2022","unstructured":"Bellamy M, Chu B, Serencsits B, Quinn B, Prasad K, Altamirano J, et al. SUBSTANTIAL EXTERNAL DOSE RATE VARIABILITY OBSERVED IN A COHORT OF LU-177 PATIENTS INDEPENDENT OF BMI AND SEX. Radiat Prot Dosimetry. 2022;198:1476\u201382.","journal-title":"Radiat Prot Dosimetry"},{"key":"2044_CR18","unstructured":"Barringtonl SF, Kettle AG, O\u2019dohertyl MJ, Wells CR, Somer EJR, Coakley~ AJ. Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid."},{"key":"2044_CR19","doi-asserted-by":"crossref","unstructured":"Levart D, Kalogianni E, Corcoran B, Mulholland N, Vivian G. Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours. EJNMMI Phys. 2019;6.","DOI":"10.1186\/s40658-019-0243-1"},{"key":"2044_CR20","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.2967\/jnumed.111.091165","volume":"52","author":"TD Poeppel","year":"2011","unstructured":"Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, et al. 68Ga-DOTATOC versus 68Ga-DOTATATE PET\/CT in functional imaging of neuroendocrine tumors. J Nucl Med. 2011;52:1864\u201370.","journal-title":"J Nucl Med"},{"key":"2044_CR21","unstructured":"Cascini GL, Cuccurullo V, Tamburrini O, Rotondo A, Mansi L. Send Orders of Reprints at reprints@benthamscience.org Peptide Imaging with Somatostatin Analogues: More than Cancer Probes. Curr Radiopharm. 2013."}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02044-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-025-02044-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02044-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T11:47:47Z","timestamp":1750160867000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-025-02044-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,5]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2044"],"URL":"https:\/\/doi.org\/10.1007\/s12149-025-02044-5","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,5]]},"assertion":[{"value":"15 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no potential conflicts of interest related to the content of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}